Ziyond Pharmaceutical

Ziyond Pharmaceutical Co., Ltd. (formerly known as Sinomune Pharmaceutical) is a leading China-based pharmaceutical company specializing in the research, development, manufacturing, and commercialization of dermatology and skin health products. The company offers a comprehensive 'head-to-toe' portfolio of over 50 commercialized products, including topical prescription drugs, over-the-counter (OTC) medicines, and efficacy-based skin care products. Its key commercialized products include Lifu (metronidazole gel), Luofu (bifonazole solution), and Jiniuer (clobetasol propionate/tretinoin ointment), which hold leading market shares in China. Ziyond's pipeline features over 30 candidate programs, including clinical-stage modified new drugs such as ZYG24002 for seborrheic dermatitis and ZYG24004 for tinea pedis. The company leverages its proprietary Topical Drug Delivery Evaluation Technology (TDDET) and Topical Product Scale-up Production (TPSP) platforms to drive formulation innovation and product development.